Huaiyan Cui

Title: Huaiyan Cui: Innovator in Insulin and Polypeptide Preparation

Introduction

Huaiyan Cui is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the preparation of insulin and polypeptide intermediates. With a total of 2 patents, his work has the potential to impact diabetes treatment and related therapies.

Latest Patents

Cui's latest patents include a novel pro-insulin aspart structure and a method for preparing insulin aspart. This innovative method involves designing the pro-insulin aspart sequence and constructing recombinant insulin aspart engineered bacteria. The process includes inducing the expression of an insulin fusion protein as an inclusion body in the engineered bacteria, followed by extraction through denaturing, renaturing enzymatic digestion, and purification operations. By modifying the recombinant leading peptide and C-peptide sequences, this method eliminates the need for a cyanogen bromide cleavage step, enhancing efficiency.

Another significant patent is the method for preparing a liraglutide intermediate polypeptide, specifically GLP-1 (7-37). This preparation method involves constructing recombinant liraglutide engineered bacteria to induce expression of a liraglutide intermediate fusion protein. The process includes denaturation, renaturation, enzyme digestion, separation, and purification to obtain the liraglutide intermediate polypeptide with a purity of 87% or more and a yield exceeding 85%.

Career Highlights

Huaiyan Cui is currently employed at Amphastar Nanjing Pharmaceuticals Inc., where he continues to advance his research in biopharmaceuticals. His innovative approaches to insulin and polypeptide preparation have positioned him as a key figure in the industry.

Collaborations

Cui collaborates with notable colleagues, including Chuangen Tang and Cheng Li, who contribute to his research endeavors and innovations.

Conclusion

Huaiyan Cui's work in the field of biopharmaceuticals, particularly in insulin and polypeptide preparation, showcases his innovative spirit and dedication to improving healthcare solutions. His contributions are poised to make a lasting impact on diabetes treatment and beyond.